Возрастной андрогенный дефицит. Современное состояние проблемы


DOI: https://dx.doi.org/10.18565/urology.2017.5.111-114

Е.А. Финагина, О.В. Теодорович, М.Н. Шатохин, С.Ю. Шеховцов, М.И. Абдуллаев, Г.Г. Борисенко, А.В. Краснов

Кафедра эндоскопической урологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России, Москва, Россия; урологический центр НУЗ «Научный клинический центр ОАО “Российские железные дороги”», Москва, Россия; кафедра урологии, андрологии и онкоурологии ФДПО ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России, Москва, Россия
В обзоре отражены современные представления по проблеме возрастного андрогенного дефицита, рассмотрены вопросы распространенности андрогенного дефицита, взаимосвязи с возрастом, сопутствующими заболеваниями, приемом фармакологических препаратов и другими факторами.
Ключевые слова: возрастной андрогенный дефицит, андрогенный дефицит, тестостерон

Литература


1. Araujo A.B., Esche G.R., Kupelian V. et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92:4241–4247.

2. Tajar A., Forti G., O’Neill, T.W. and EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Aging Study. J Clin Endocrinol Metab. 2010;95:1810–1818.

3. Corona G., Maseroli E., Rastrelli G. et al. Characteristics of compensated hypogonadism in patients with sexual dysfunction. J Sex Med. 2014; 11: 1823–1834.

4. Wang C., Nieschlag E., Swerdloff R., Behre H., Hellstrom W., Gooren L. et al. Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl. 2009;30: 1–9.

5. Kato Y., Nomura A., Stemmermann Y.N. et al. Determinants of sex hormone levels in men as useful induces in hormone–related disorders. J. Clin. Epidemiol. 1992;45(12):1417–1421.

6. Bhasin S. Approach to the patient Approach to the Infertile Man. J Clin Endocrinology Metabolism. 2007;92(7):1996–2004.

7. Veldhuis J.D., Roemmich J.N., Richmond E.J., Bowers C.Y. Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition. Endocrine Rev. 2006;27(2):101–140.

8. Oettel M. Naturwissenschaften. 2004;91:66.

9. Wu F.C., Tajar A., Beynon J.M. and EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363:123–135.

10. Maseroli E., Corona G., Rastrelli G. et al. Prevalence of endocrine and metabolic disorders in subjects with erectile dysfunction: a comparative study. J Sex Med. 2015; 12: 956–965.

11. Corona G., Maggi M. Perspective: regulatory agencies’ changes to testosterone product labeling. J Sex Med. 2015;12:1690–1693.

12. Nieschlag E., Lammers U., Freischem C.W., Langer K., Wickings E.J. Reproductive functions in young fathers and grandfathers. J Clin Endocrinol Metab. 1982;55:676–668.

13. Yeap B.B., Almeida O.P., Hyde Z. et al. Healthier lifestyle predicts higher circulating testosterone in older men: the Health In Men Study. Clin Endocrinol (Oxf). 2009; 70: 455–463.

14. Sartorius G., Spasevska S., Idan A. et al. Serum testosterone, dihydrotestosterone and estradiol concentrations in older men self-reporting very good health: the healthy man study. Clin Endocrinol (Oxf). 2012; 77: 755–763.

15. Harman S.M., Metter E.J., Tobin J.D., Pearson J., Blackman M.R., and Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001; 86: 724–731.

16. Araujo A.B., O’Donnell A.B., Brambilla D.J. et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study.J Clin Endocrinol Metab. 2004;89:5920–5926.

17. Wu F.C., Tajar A., Pye S.R. and European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab. 2008; 93: 2737–2745.

18. Feldman H.A., Longcope C., Derby C.A. et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study.J Clin Endocrinol Metab. 2002; 87: 589–598.

19. Laaksonen D.E., Niskanen L., Punnonen K. et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004; 27: 1036–1041.

20. Laaksonen D.E., Niskanen L., Punnonen K. et al. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab. 2005; 90: 712–719.

21. Allan C.A., McLachlan, R.I. Androgens and obesity. Curr Opin Endocrinol Diabetes Obes. 2010;17: 224–232.

22. MacDonald A.A., Herbison G.P., Showell M., Farquhar C.M. The impact of body mass index on semen parameters and reproductive hormones in human males: a systematic review with meta-analysis. Hum Reprod Update. 2010; 16: 293–311.

23. Brand J.S., van der Tweel I., Grobbee D.E., Emmelot-Vonk M.H., and van der Schouw Y.T. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol. 2011;40:189–207.

24. Wang C., Jackson G., Jones, T.H. et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34:1669–1675.

25. Novikova E.G., Selyatickaya V.G., Lutov, Yu.V., Mitrofanov I.M. The relationship of hypogonadism with metabolic syndrome in men of different age groups. Vestnik NGU. 2012;10(1):54–62. Russian. (Новикова Е.Г., Селятицкая В.Г., Лутов Ю.В., Митрофанов И.М. Связь гипогонадизма с метаболическим синдромом у мужчин разных возрастных групп. Вестник НГУ. 2012;10(1):54–62).

26. Ding E.L., Song Y., Malik V.S., Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006; 295: 1288–1299.

27. Shores M.M., Matsumoto A.M., Sloan K.L., Kivlahan D.R. Low serum testosterone and mortality in male veterans. Arch Intern Med. 2006; 166: 1660–1665.

28. Corona G., Mannucci E., Schulman C. et al. Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction. Eur Urol. 2006;50:595–604.

29. Corona G., Vignozzi L., Sforza A., Mannucci E., Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120–133.

30. Muller M., den Tonkelaar I., Thijssen J., Grobbee D., Van der Schouw Y. Endogenous sex hormones in men aged 40–80 years. Eur. J Endocrinol. 2003;149:583–589.

31. Pecherskij A.V., Dombrovskaya Yu. A., Pecherskaya O.V. The role of partial age-related androgen deficiency in the development of insulin resistance and disorders of microcirculation. Materials of the International Congress on Andrology. Sochi, Dagomys, 2009. P. 132. Russian. (Печерский А.В., Домбровская Ю.А., Печерская О.В. и др. Роль частичного возрастного андрогенного дефицита в развитии инсулинорезистентности и нарушений микроциркуляции. Материалы Международного Конгресса по андрологии. Сочи, Дагомыс, 2009. С. 132).

32. Vorslov L.O., Morgunov L.Yu. The relationship between a decrease in testosterone levels in men and a violation of lipid metabolism. Terapevt. 2007;12: 59–65. Russian (Ворслов Л.О., Моргунов Л.Ю. Взаимосвязь между снижением уровня тестостерона у мужчин и нарушением липидного обмена. Терапевт. 2007;12:59–65).

33. Frolov D.S., Halimov Yu.S., Shustov S.B. Age-related androgen deficiency in men with ischemic heart disease. Problemy endokrinologii. 2011;57(2):19–22. Russian (Фролов Д.С., Халимов Ю.Ш., Шустов С.Б. Возрастной андрогенный дефицит у мужчин с ишемической болезнью сердца. Проблемы эндокринологии. 2011;57(2):19–22).

34. Tyuzikov I.A., Grekov EA Kalinchenko S.Yu. Features of clinical course and morphometric parameters of benign prostatic hyperplasia in men with metabolic syndrome and androgen deficiency. Urologiia. 2015;(5):66–69. Russian (Тюзиков И.А., Греков Е.А., Калинченко С.Ю. Особенности клинического течения и морфометрических параметров доброкачественной гиперплазии предстательной железы у мужчин с метаболическим синдромом и андрогенным дефицитом. Урология. 2015;5:66–69).

35. Tyuzikov I.A., Martov А.G., Kalinchenko S.Yu. Influence of obesity and androgen deficiency on prostatic blood circulation. Byulleten Sibirskoj mediciny. 2012;2:80–83. Russian (Тюзиков И.А., Мартов А.Г., Калинченко С.Ю. Влияние ожирения и андрогенного дефицита на кровообращение предстательной железы. Бюллетень Сибирской медицины. 2012;2:80–83).

36. Mulligan T., Frick M.F., Zuraw Q.C., Stemhagen A., McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60:762–769.

37. Bonin-Guillaume S., Herrmann F.R., Boillat D., Szanto I., Michel J.P., Rohner-Jeanrenaud F., Vischer U.M. de Carvalho, Colaco A.L. Fortes Z.B. Cytokines, endothelial dysfunction, and insulin resistance. Arq. Bras. Endocrinol. Metabol. 2006;2(50):304–312.

38. Guzder R.N., Gatling W., Mullee M.A., Byrne C.D. Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. Diabetologia. 2006;49(11):49–55.

39. Ashby J., Goldmeier D., Sadeghi-Nejad H. Hypogonadism in human immunodeficiency virus-positive men. Korean J Urol. 2014;55:9–16.

40. Wong N., Levy M., Stephenson I. Hypogonadism in the HIV-Infected Man. Curr Treat Options Infect Dis. 2017;9(1):104–116.

41. Attal P., Chanson P. Endocrine aspects of obstructive sleep apnea. J Clin Endocrinol Metab. 2010;95:483–495.

42. Gambineri A., Pelusi C., Pasquali R. Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters. J Endocrinol Invest. 2003; 26: 493–498.

43. Luboshitzky R., Aviv A., Hefetz A. et al. Decreased pituitary-gonadal secretion in men with obstructive sleep apnea. J Clin Endocrinol Metab. 2002; 87: 3394–3398.

44. Singer F., Zumoff B. Subnormal serum testosterone levels in male internal medicine residents. Steroids. 1992;57:86–89.

45. Nilsson P.M., Møller L., Solstad K. Adverse effects of psychosocial stress on gonadal function and insulin levels in middle-aged males. J Intern Med. 1995;237:479–486.

46. Woolf P.D., Hamill R.W., McDonald J.V., Lee L.A., Kelly M. Transient hypogonadotropic hypogonadism caused by critical illness. J Clin Endocrinol Metab. 1985; 60: 444–450.

47. Thompson S.T. Prevention of male infertility. Urol Clin North Am. 1994;21:365–376.

48. Rahnema C.D., Lipshultz L.I., Crosnoe L.E., Kovac J.R., Kim E.D. Anabolic steroid-induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101:1271–1279.

49. Morrison D., Capewell S., Reynolds S., Thomas J., Ali N., Read G., et al. Testosterone levels during systemic and inhaled corticosteroid therapy. Respir Med. 1994;88:659–663.

50. Birthi P., Nagar V.R., Nickerson R., Sloan, P.A. Hypogonadism associated with long-term opioid therapy: a systematic review. J Opioid Manag. 2015; 11: 255–278.

51. Rajagopal A., Vassilopoulou-Sellin R., Palmer J., Kaur G., Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851–858.

52. Katz N., Mazer N. The impact of opioids on the endocrine system. Clin J Pain. 2009;25:170–175.

53. Schooling C.M., Au Yeung S.L., Freeman G., Cowling B.J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57.

54. Rosen R., Kostis J., Jekelis A. Beta-blocker effects on sexual function in normal males. Arch Sex Behav. 1988;17: 241–255.

55. Howell S.J., Shalet S.M. Spermatogenesis after cancer treatment: damage and recovery.J Natl Cancer Inst Monogr. 2005;34:12–17.

56. Thompson I., Goodman P., Tangen C., Lucia M., Miller G., Ford L. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349: 215–224.


Об авторах / Для корреспонденции


А в т о р д л я с в я з и: Е. А. Финагина – аспирант кафедры эндоскопической урологии ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; Москва, Россия; e-mail: lizafinagina@mail.ru


Бионика Медиа